PTC Therapeutics (NASDAQ:PTCT) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $(1.42) by 114.09 percent. This is a 114.39 percent increase over losses of $(1.39) per share from the same period last year. The company reported quarterly sales of $211.007 million which beat the analyst consensus estimate of $185.251 million by 13.90 percent. This is a 7.23 percent increase over sales of $196.786 million the same period last year.